Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular Clinical Trial

— RENOBATE  

Official title:

Phase II Study of Regorafenib-nivolumab Combination Therapy for Chemotherapy-naïve Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04310709
• Other study ID #: RENOBATE
• Status: Completed
• Phase: Phase 2
• Start date: June 16, 2020
• Est. completion date: November 30, 2022

Study information

• Verified date: December 2022
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Regorafenib and nivolumab are proven effective agents for the management of unresectable hepatocellular carcinoma patients. As preclinical studies have suggested potential synergism between antiangiogenic agents and immune checkpoint inhibitors, regorafenib and nivolumab may have synergism in terms of efficacy. Herein, this study investigates the combination of regorafenib and nivolumab as first-line therapy in patients with unresectable hepatocellular carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: November 30, 2022
• Est. primary completion date: May 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Age = 19 years at time of signing Informed Consent Form

2. Ability to comply with the study protocol, in the investigator's judgment

3. HCC that was histologically/cytologically confirmed or clinically diagnosed by AASLD criteria in cirrhotic patients. Patients without liver cirrhosis require histological confirmation of HCC

4. Locally advanced unresectable or metastatic disease that is not amenable to curative surgical and/or locoregional therapies, or that progressed after surgical and/or locoregional therapies

5. No prior systemic therapy for HCC

6. At least one measurable (per RECIST 1.1) lesion as confirmed by imaging within 28 days prior to initiation of study treatment

7. Patients who received prior local therapy (e.g., radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization, etc.) are eligible provided that other target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST 1.1.

8. Pre-treatment tumor tissue sample (if available)

• If tumor tissue is available, approximately 10 to 30 slides containing unstained, freshly cut, serial sections will be required subsequently for translational research.
• If tumor tissue is not available (e.g., depleted because of prior diagnostic testing), patients are still eligible.

9. ECOG Performance Status score 0 or 1

10. Child-Pugh class A

11. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment, unless

otherwise specified:

• ANC = 1.0 x 109/L (1000/microL) without granulocyte colony-stimulating factor support
• Platelet count = 75 x 109/L (75,000/mciroL) without transfusion
• Hemoglobin = 90 g/L (9 g/dL): Patients may be transfused to meet this criterion.
• AST, ALT, and alkaline phosphatase (ALP) = 3 x upper limit of normal (ULN)
• Serum bilirubin = 2 x ULN
• Serum creatinine = 1.5 x ULN or creatinine clearance = 50 mL/min (calculated using the Cockcroft-Gault formula)
• Serum albumin = 28 g/L (2.8 g/dL)
• For patients not receiving therapeutic anticoagulation: INR or aPTT = 2 x ULN
• Urine dipstick for proteinuria < 2+
• Patients discovered to have = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.

12. Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade = 1 prior to study entry, with the exception of alopecia

13. Negative HIV result at screening test or prior tested conducted within 3 years

14. Documented virology status of hepatitis, as confirmed by screening HBV and HCV serology test

• Patients with active hepatitis B virus (HBV) must meet the followings: HBV DNA < 500 IU/mL obtained within 14 days prior to initiation of study treatment, anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study

15. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons)#1 must agree to use contraception#2 from the time of informed consent until 5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.

16. Men must agree to use contraception #2 from the start of study treatment until 7 months or more after the last dose of the investigational product.

Exclusion Criteria:

1. Patients who are diagnosed with fibrolamellar HCC, sarcomatoid HCC, or combined type of cholangiocarcinoma and HCC

2. Patients with a history of malignancy other than HCC within 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, and Stage I uterine cancer

3. Patients with a history of leptomeningeal seeding

4. Patients with symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

• Asymptomatic patients with treated CNS lesions are eligible, provided that all of

the following criteria are met:

1. The patients must have at least one measurable lesion, per RECIST 1.1, other than CNS metastases

2. The patient must not have a history of intracranial hemorrhage or spinal cord hemorrhage

3. The metastatic lesions have to be limited in cerebellum or supratentorial region (e.g., not to the midbrain, pons, medulla, or spinal cord)

4. There must be no evidence of interim progression between the completion of CNS-directed therapy and initiation of the study treatment

5. The patient must not undergo stereotactic radiotherapy within 7 days, whole-brain radiotherapy within 14 days, or neurosurgical resection within 28 days prior to initiation of the study treatment

6. The patient must not have ongoing requirement for corticosteroids for CNS disease

• Anticonvulsant therapy at a stable dose is permitted.
• Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan.

5. Patients with current of past history of autoimmune disease or immunodeficient disease (including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjo¨gren syndrome,

Guillain-Barre´ syndrome, or multiple sclerosis) with the following exceptions:

• Patients with autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible.
• Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible.
• Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are

met:

1. Rash must cover < 10% of body surface area

2. Disease has to be well controlled at baseline and requires only low-potency topical corticosteroids

3. There must be no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months

6. Patients with current or past history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.

• Patients with history of radiation pneumonitis in the radiation field (fibrosis) are eligible if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.

7. Patients who have experienced a transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 6 months before initiation of study treatment

8. Patients with a history of uncontrollable or significant cardiovascular disease

meeting any of the following criteria:

• Myocardial infarction within 6 months before initiation of study treatment
• Uncontrollable angina pectoris within 6 months before initiation of study treatment
• New York Heart Association Class II or greater congestive heart failure within 6 months before initiation of study treatment
• Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure =150 mmHg or diastolic blood pressure > 90 mmHg based on an average of = 3 BP readings on = 2 sessions)
• Arrhythmia requiring treatment

9. Patients with congenital long QT syndrome or corrected QT interval >450 ms (calculated with use of the Fridericia method) at screening

10. Patients with systemic infections (including active tuberculosis) requiring treatment

11. Patients with history of hypertensive crisis or hypertensive encephalopathy

12. Patients with significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to initiation of study treatment

13. Patients who underwent major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment or who are expected to need a major surgical procedure during the study

14. Patients who have received radiotherapy within 28 days before initiation, or radiotherapy to bone metastases within 14 days before initiation

15. Patients with prior history of allogeneic stem cell or solid organ transplantation

16. Patients with current or past history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins

17. Patients with untreated or incompletely treated varices with active bleeding or high risk for bleeding

18. Patients with moderate or severe ascites

19. Patients with history of hepatic encephalopathy

20. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

21. Patients who had recent (within 10 days of first dose of study treatment) use of aspirin (> 300 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol

22. Patients who had recent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose

• Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR < 1.5 x ULN and aPTT within normal limits within 14 days prior to initiation of study treatment.
• Prophylactic use of low molecular-weight heparin (i.e., enoxaparin 40 mg/day) is allowed.

23. Patients who treated with strong CYP3A4 inducers within 14 days prior to initiation of study treatment, including rifampin (and its analogues) or St. John's wort

24. Patients who have previously received CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies

25. Patients who were treated with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment

26. Patients who were treated with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during

study treatment, with the following exceptions:

• Patients who received temporary, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.
• Patients who received mineralocorticoids (e.g., fludrocortisone), or corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.

27. Patients who had abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment

28. Patients who had intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding within 6 months prior to initiation of study treatment

• Patients with signs/symptoms of sub-/occlusive syndrome/intestinal obstruction at time of initial diagnosis may be enrolled if they had received definitive (surgical) treatment for symptom resolution.

29. Women who are pregnant or breastfeeding, or possibly pregnant

30. Other patients judged by the investigator or sub-investigator to be inappropriate as subjects of this study

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatoma

Intervention

Drug:
• Regorafenib/Nivolumab
Combination of regorafenib and nivolumab

Locations

Country	Name	City	State
Korea, Republic of	Bundang CHA Hospital	Seongnam
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (3)

Lead Sponsor	Collaborator
Asan Medical Center	Bundang CHA Hospital, Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (4)

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum In: Lancet. 2017 Jan 7;389(10064):36. — View Citation

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. — View Citation

Yoo C, Park JW, Kim YJ, Kim DY, Yu SJ, Lim TS, Lee SJ, Ryoo BY, Lim HY. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Invest New Drugs. 2019 Jun;37(3):567-572. doi: 10.1007/s10637-018-0707-5. Epub 2018 Dec 7. — View Citation

Yoo C, Ryu YM, Kim SY, Kim J, Ock CY, Ryu MH, Kang YK. Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours. Br J Cancer. 2019 Nov;121(10):819-826. doi: 10.1038/s41416-019-0596-1. Epub 2019 Oct 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate	Proportion of patients with complete response/partial response graded by Response Criteria in Solid Tumor version 1.1	6 months
Secondary	Adverse events	Proportion of patients experiencing adverse events graded by National Cancer Institute Common Terminology Criteria version 5.0	1 year
Secondary	Progression-free survival	Time between the start of study treatment and progressive disease or any cause of death	1 year
Secondary	Overall survival	Time between the start of study treatment and any cause of death	1 year